Americas Sleep Apnea Market

The Americas sleep apnea market is expected to grow from $ 2,454.20 million in 2022 and is expected to reach to a value of US$ 4,103.24 million by 2030, it is anticipated to record a CAGR of 6.6% from 2022 to 2030.

The driving factors include increasing prevalence of sleep apnea and growing demand for sleep apnea diagnostic devices and therapeutic solutions. However, low awareness of sleep apnea is hampering the Americas sleep apnea market growth.

Many market players and research institutes operating in the Americas sleep apnea market are developing advanced products to expand their product portfolios and increase their market shares. They invest significant amounts in R&D to develop advanced products. A few of the recent developments related to sleep apnea are mentioned below:

In September 2021, Cadwell is proud to announce the release of the E3 cart for the Easy III PSG and EEG systems into the USA Market. The E3 Cart is designed to be an ergonomic, mobile workstation with optimal shelf and storage space for accessories commonly used in a sleep lab, such as CPAP equipment, Transcutaneous CO2 monitors and a EtCO2 monitors.

In September 2021, Philips anticipates rework to commence in the course of September 2021. In addition to the rework, the company has already started replacing certain affected first-generation DreamStation CPAP devices in the US with DreamStation 2 CPAP devices.

Thus, such development are likely to introduce new trends in the Americas sleep apnea market during the forecast period.

Constant technological advancements and awareness regarding sleep apnea are boosting the adoption of various medical devices, such as PSG and home sleep testing. Many industry players are focusing on innovative product strategies to meet the growing demand for sleep apnea diagnostic devices. For instance, in August 2021, ResMed successfully launched "AirSense 11," the first available in the US. It is the company's next-generation positive airway pressure device designed to assist people suffering from sleep apnea. In August 2020, Nihon Koden Corporation announced the launch of Polysmith 12 polysomnography software. The Polysmith software includes more than 40 market-driven features that offer sleep specialists to improve workflow, analysis, and outcomes of the medical device. The new product also offers a cost-effective design with a broad range of features, such as the enhancement of scheduling, prioritization, and email notification capabilities for enhanced workflow, improved status tracking to organize patients based on priority and status, and the ability to track patient progress to improve clinical outcomes. In September 2021, Sommetrics, a pioneer in manufacturing products and services to improve sleep health, announced the launch of a pivotal clinical trial for the "aerSleep II device" for the treatment of OSA. The company termed the clinical trial as "SUPRA study" (i.e., Study Using Negative Pressure to Reduce Sleep Apnea). The trial aims to evaluate the treatment benefits and safety of applying a mild external vacuum over the upper way airway with the aerSleep II device. Thus, such innovative product launches and clinical trials are projected to offer lucrative opportunities to the market players during the forecast period.

Type-Based Insights

Based on type, the global Americas sleep apnea market is segmented into diagnostic devices and therapeutic devices. Diagnostic devices is further sub-segmented as polysomnography devices (PSG), home sleep testing devices, pulse oximeters, actigraphy devices, and others. Therapeutic devices is further sub-segmented as PAP, sleep masks, oral appliances, and others. The therapeutics segment held the largest market share in 2022 and diagnostic devices is anticipated to register the highest CAGR of 7.4% during the forecast period (2022–2030).

End-User-Based Insights

Based on end-user, the Americas sleep apnea market, is segmented into hospitals, homecare settings, and others. The hospitals segment held the largest share of the market in 2022 and homecare settings is expected to grow at the highest CAGR during the forecast period.

A few of the major primary and secondary sources referred to while preparing the report on the Americas sleep apnea market are the World Health Organization (WHO), the US Census Bureau, and the US National Library of Medicine, among others.